FDA Brief

Warning letters Drugs

FDA warning letter to

Horizon Tool Inc.

High riskIssued Jun 6, 2025Posted Jun 17, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.

What happened

FDA inspected Horizon Tool's Greensboro, NC drug manufacturing facility from January 14 to 16, 2025. FDA found the company lacked required microbiological testing for each batch of AllShield E2 Sanitizing Hand Soap, had no stability testing program for it, and did not adequately test incoming components, including benzalkonium chloride.

What FDA found

  1. The company did not test each batch of AllShield E2 Sanitizing Hand Soap for objectionable microorganisms before release.

    21 CFR 211.165(b)
  2. The company did not establish or follow a written stability testing program for AllShield E2 Sanitizing Hand Soap.

    21 CFR 211.166(a)
  3. The company did not adequately test incoming components, including active ingredients and benzalkonium chloride solution, for identity and other required specifications.

    21 CFR 211.84(d)(1) and 211.84(d)(2)

What FDA wants

FDA asks Horizon Tool to respond in writing within 15 working days with corrective actions, supporting documentation, independent assessments, and retrospective risk assessments for distributed batches. If the company cannot complete the actions in that time, it must give reasons and a completion schedule.

Who should pay attention

  • brands that sell OTC antibacterial soaps
  • contract manufacturers of OTC topical drug products
  • suppliers and buyers of benzalkonium chloride or other drug ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk